Joe Rogan and Aaron Siri Get a Few Basics of Vaccine Law Right — But the Interview Quickly Turns into Sensationalized Baseless Rhetoric
Joe Rogan and Aaron Siri discussed vaccine law and vaccine court. They get a few things right about the Vaccine Injury Compensation Program—and where the interview goes wrong.
The recent Joe Rogan Experience interview with attorney Aaron Siri has sparked widespread discussion about vaccine law, vaccine court, and the Vaccine Injury Compensation Program (VICP). In the conversation, Siri raises several issues about vaccine liability protections, the 1986 National Childhood Vaccine Injury Act, and the legal framework that governs vaccine injury claims in the United States. Some of these points are correct and deserve public attention. However, much of the discussion mixes legitimate legal concepts with misleading rhetoric and inaccurate claims about vaccine science and vaccine safety. Understanding what the Vaccine Injury Compensation Program actually does—and how vaccine injury claims are handled in the United States—is essential for separating fact from sensationalism.
The Existence of the Vaccine Injury Compensation Program
One of the most important facts mentioned during the interview is that the United States operates a federal vaccine injury compensation system.
The National Vaccine Injury Compensation Program (VICP) was created by Congress in 1986 through the National Childhood Vaccine Injury Act. The program allows individuals who believe they were injured by certain vaccines to file claims in the U.S. Court of Federal Claims, where cases are decided by judicial officers known as Special Masters within the Office of Special Masters.
The VICP functions as a no-fault vaccine injury compensation system. Rather than requiring injured individuals to prove negligence or wrongdoing by a vaccine manufacturer or healthcare provider, the program evaluates whether the evidence shows that the vaccine more likely than not caused the injury. If causation is established, the program may award compensation for medical expenses, lost wages, pain and suffering, and other damages.
Since the program began operating in 1988, billions of dollars have been paid to individuals and families through the Vaccine Injury Compensation Program.
Despite this, most Americans have never heard of the VICP or understand how vaccine injury claims are handled in the United States. Public awareness of the program remains surprisingly low. The Department of Health and Human Services and the broader medical community have historically done very little to educate the public about the existence of the program or how individuals can access it.
As a result, much of the public education about vaccine injury compensation actually comes from attorneys who practice in vaccine court and represent injured petitioners.
That lack of public awareness is a legitimate issue.
The Supreme Court Limited Certain Vaccine Lawsuits
The interview also correctly references the Supreme Court’s decision in Bruesewitz v. Wyeth (2011).
In that case, the Supreme Court held that the National Childhood Vaccine Injury Act largely preempts design defect lawsuits against vaccine manufacturers for vaccines covered under the Vaccine Injury Compensation Program. In practical terms, the Court concluded that Congress intended the VICP to serve as the primary forum for resolving vaccine injury claims rather than traditional product liability litigation.
However, the decision did not eliminate all potential lawsuits against vaccine manufacturers. Claims based on manufacturing defects or failure to warn may still be brought under certain circumstances.
Importantly, the Vaccine Act requires that a vaccine injury claim first proceed through the Vaccine Injury Compensation Program before a claimant may pursue civil litigation. After filing a claim in vaccine court, a petitioner may choose to opt out of the VICP after 240 days and pursue a traditional civil lawsuit, particularly if the claim involves allegations of manufacturing defects or inadequate warnings.
This legal structure is unusual, but it was created for a specific reason: to maintain a stable vaccine supply while still providing a forum for injured individuals to seek compensation.
The VICP removes one of the most difficult hurdles present in traditional pharmaceutical litigation. Petitioners in vaccine court do not need to prove that the vaccine was defectively designed. Instead, they must demonstrate that the vaccine caused their injury.
In traditional product liability litigation, proving that a pharmaceutical product was defectively designed can be extraordinarily difficult. Vaccines are typically effective and safe for the overwhelming majority of individuals. Demonstrating that a vaccine was defective in a very small number of cases can therefore be a substantial evidentiary challenge.
The VICP was designed to lower that burden and provide a more accessible path to compensation for legitimate vaccine injuries.
Pharmaceutical Companies Do Have Significant Political Influence
Another point raised in the interview is the influence of pharmaceutical companies in the political process.
Like many large industries, pharmaceutical companies engage in lobbying and political advocacy. This is a common feature of modern regulatory systems and occurs across a wide range of sectors, including technology, energy, healthcare, and finance.
Large corporations often lobby Congress and federal agencies in order to influence policy decisions that affect their industries. While this dynamic can raise important questions about regulatory capture and industry influence, it is not unique to vaccines or the pharmaceutical industry.
At the same time, it is important to recognize that the structure created by the National Childhood Vaccine Injury Act reflects a negotiated policy framework that many stakeholders—including those who represent vaccine-injured individuals—continue to support.
Attorneys who represent injured petitioners in vaccine court, many of whom are members of the Vaccine Injured Petitioners Bar Association (VIP Bar), have historically supported the existence of the Vaccine Injury Compensation Program. The VICP provides a specialized forum where injured individuals can seek compensation without needing to prove manufacturer negligence or product defect.
The program is funded through an excise tax on each covered vaccine dose, which is deposited into the Vaccine Injury Compensation Trust Fund. That trust fund currently contains billions of dollars dedicated specifically to compensating individuals who can prove that a vaccine caused their injury.
For many practitioners who work in this field, the goal is not to dismantle the Vaccine Injury Compensation Program or create broad new avenues to sue manufacturers. If the objective is to ensure that injured individuals receive compensation, the VICP often provides a more efficient and realistic path to recovery than traditional pharmaceutical litigation.
As a result, many attorneys who represent vaccine-injured petitioners focus their efforts on preserving and improving the VICP rather than eliminating it.
Transparency From Public Health Agencies Matters
The Rogan interview also emphasizes the importance of transparency from public health agencies such as the Centers for Disease Control and Prevention and the Food and Drug Administration.
On this point, many people across the political spectrum agree. Transparency about regulatory decisions, safety monitoring, and scientific evidence is essential for maintaining public trust in vaccines and public health institutions.
At the same time, it is important to distinguish between calls for transparency and allegations that the underlying data itself is fraudulent or compromised. There is no credible evidence that vaccine safety data produced by agencies such as the CDC, FDA, or National Institutes of Health is systematically falsified, manipulated, or fraudulent.
Vaccines undergo extensive clinical testing, regulatory review, and post-licensure safety monitoring through systems such as the Vaccine Adverse Event Reporting System (VAERS) and other federal surveillance programs. These systems are designed to detect rare adverse events and continuously evaluate vaccine safety in the population.
Calls for transparency and accountability in public health policy are legitimate and important. However, where the Rogan interview begins to go off course is in how these legitimate concerns are used to support much broader claims about vaccine safety that are not supported by the scientific evidence.
Criticism of regulatory decisions should not automatically be conflated with claims that the entire system of vaccine safety monitoring is fundamentally corrupt or fraudulent.
Maintaining that distinction is essential for having a serious and productive public conversation about vaccines, vaccine policy, and vaccine injury compensation.
Unpacking the False Rhetoric from the Joe Rogan - Aaron Siri Podcast
Claim: “Vaccines Are the Only Product You Cannot Sue Over”
The framing used in the Rogan interview suggests that the inability to sue vaccine manufacturers in traditional product liability litigation represents a denial of justice. But this argument misunderstands the fundamental purpose of injury litigation.
The purpose of a product liability lawsuit is ultimately to obtain compensation for an alleged injury. Whether that compensation comes through a jury verdict or through a statutory compensation system does not change the underlying objective: providing financial recovery for individuals who can demonstrate that a product caused harm.
Congress recognized this when it created the Vaccine Injury Compensation Program in 1986. Rather than forcing injured individuals to navigate complex pharmaceutical litigation, Congress created a specialized compensation system with a lower evidentiary burden. Petitioners in vaccine court do not need to prove that a vaccine was defectively designed or manufactured. Instead, they must demonstrate that it is more likely than not that the vaccine caused the injury.
This distinction is important because many vaccine injuries do not arise from defective products in the traditional sense. Vaccines are designed to stimulate the immune system. In rare cases, an individual’s immune response may become abnormal or dysregulated, leading to neurological or autoimmune complications. In those situations, the vaccine itself may function exactly as intended while still triggering an adverse outcome in a susceptible individual.
Traditional product liability law is poorly suited to address these kinds of cases because it focuses on whether a product was defectively designed or manufactured. The Vaccine Injury Compensation Program instead focuses on the central question that matters most to injured individuals: did the vaccine cause the injury?
By removing the need to prove defect and replacing it with a causation-based standard, Congress created a system that can actually make compensation more accessible rather than less.
The debate therefore should not be framed around whether injured individuals can sue vaccine manufacturers. The more relevant question is whether individuals who experience rare vaccine injuries have access to a compensation system that is fair, efficient, and capable of evaluating complex medical evidence.
That is precisely the role the Vaccine Injury Compensation Program was designed to serve.
Claim: “The Vaccine Act Was Passed Because Vaccines Were Causing So Much Harm”
Another assertion made during the interview is that the National Childhood Vaccine Injury Act of 1986 was passed because vaccines were causing widespread harm.
The historical record shows something very different.
The Vaccine Act was enacted during the early 1980s after a surge in product liability litigation created a liability crisis for vaccine manufacturers. As lawsuits increased, the number of companies willing to manufacture vaccines declined sharply. By the mid-1980s, the number of vaccine manufacturers in the United States had fallen dramatically—from approximately 18 companies to only four producing vaccines for the U.S. market.
Congress became concerned that continued litigation could destabilize the national vaccine supply and potentially lead to shortages of essential vaccines used in childhood immunization programs. Historical analyses of the period confirm that policymakers feared the United States might lose the capacity to produce certain vaccines entirely if manufacturers continued to exit the market due to liability exposure. (See Institute of Medicine, Adverse Effects of Vaccines: Evidence and Causality; JAMA Pediatrics, historical review of the Vaccine Injury Compensation Program.)
The Vaccine Act was therefore designed to solve two problems simultaneously.
First, it created a federal compensation system for individuals who experience rare vaccine injuries. Second, it stabilized the vaccine market by reducing the unpredictability and cost of traditional product liability litigation.
The structure of the law reflects a negotiated policy compromise. Vaccine manufacturers agreed to fund a compensation system through a federal excise tax on each covered vaccine dose, which is deposited into the Vaccine Injury Compensation Trust Fund. In exchange, most vaccine injury claims would first proceed through the Vaccine Injury Compensation Program rather than through traditional civil litigation.
Importantly, the creation of the VICP was not based on a conclusion that vaccines were causing widespread harm. Rather, it reflected a practical recognition by Congress, attorneys representing injured individuals, and vaccine manufacturers that traditional civil litigation was poorly suited to resolving vaccine injury claims.
In many vaccine injury cases, the injury alleged is not the result of a defective product in the conventional sense. Vaccines function by stimulating the immune system. In rare cases, that immune response may become abnormal or dysregulated in a particular individual. Proving in civil court that a vaccine increased the risk of a specific injury would often require large epidemiological studies or scientific evidence that simply does not exist for extremely rare conditions.
Congress recognized that attempting to prove these cases under traditional tort standards would often be impossible. The problem would become even more difficult after the Supreme Court’s Daubert v. Merrell Dow Pharmaceuticals (1993) decision, which significantly tightened the evidentiary standards governing expert testimony in civil litigation.
The Vaccine Injury Compensation Program was therefore designed as a more flexible and scientifically informed forum where claims could be evaluated using a lower evidentiary standard focused on causation rather than product defect.
In short, the Vaccine Act was not passed because vaccines were causing widespread harm. It was passed because policymakers recognized that the existing tort system could neither reliably compensate injured individuals nor preserve the stability of the national vaccine supply.
The VICP was created to accomplish both goals.
Claim: “Vaccines Are Not Tested Like Other Medical Products”
The interview also suggested that vaccines are uniquely unsafe because they are not tested with long-term placebo-controlled trials. This claim misunderstands how vaccine development and clinical trials work in modern medicine.
Vaccines undergo a rigorous, multi-stage scientific process that typically takes 10–15 years from early research to regulatory approval. In the United States, vaccine development and licensure are overseen by the Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER), which regulates vaccines and other biological products. Each stage of development is designed to evaluate safety, effectiveness, and manufacturing quality before a vaccine can be licensed for public use. (FDA, Vaccine Development – 101; CDC, Ensuring the Safety of Vaccines in the United States).
How Vaccine Development and Clinical Trials Work
Vaccine development typically proceeds through several stages.
1. Preclinical research
Before a vaccine is ever tested in humans, it undergoes extensive laboratory and animal testing. During this stage, researchers evaluate the biological mechanism of the vaccine candidate and determine whether it produces the desired immune response. Scientists also study potential toxicity, dosing levels, and how the immune system responds to the vaccine antigen.
Preclinical research often involves cell culture experiments and animal models to identify potential safety concerns before human trials begin. These studies help determine whether a vaccine candidate is likely to be safe enough to move into human testing and whether it generates an immune response capable of protecting against disease. (World Health Organization, Vaccine Safety Basics; Plotkin, Orenstein & Offit, Vaccines, 7th ed.).
2. Phase I clinical trials
If preclinical research shows promising results, the vaccine candidate moves into Phase I clinical trials, the first stage of testing in humans.
Phase I trials typically involve 20 to 100 healthy volunteers. The primary goal at this stage is to evaluate safety and determine appropriate dosing. Researchers carefully monitor participants for side effects and collect preliminary data about the immune response produced by the vaccine.
Because vaccines are given to healthy individuals—often including children—safety monitoring during Phase I trials is particularly rigorous. Investigators track both short-term reactions, such as fever or soreness at the injection site, and early indicators of immune response. (FDA Center for Biologics Evaluation and Research; National Institute of Allergy and Infectious Diseases).
3. Phase II clinical trials
Phase II trials expand the study population to several hundred participants and continue evaluating safety while refining dosing schedules and assessing immune responses across different age groups.
At this stage, researchers determine the optimal number of doses, spacing between doses, and whether the vaccine produces a consistent immune response across populations that will eventually receive the vaccine. These trials also provide additional safety data and help identify less common side effects. (CDC, Vaccine Testing and the Approval Process; WHO Vaccine Development Guidelines).
4. Phase III clinical trials
Phase III clinical trials are the largest and most comprehensive stage of vaccine testing before regulatory approval. These studies typically involve thousands to tens of thousands of participants across multiple clinical sites.
Participants are divided into groups that receive either the vaccine candidate or a control intervention. Researchers then monitor participants over time to determine how well the vaccine prevents disease and to identify rare adverse events that may occur.
Because rare side effects may only appear when a vaccine is administered to large numbers of people, Phase III trials are critical for establishing a vaccine’s safety profile. For many vaccines, these trials involve tens of thousands of participants followed over extended periods before regulators review the data.
After reviewing Phase III results, the FDA evaluates the vaccine’s safety, effectiveness, manufacturing processes, and quality control systems before granting licensure. (FDA, Vaccine Development and Approval Process; Institute of Medicine, Adverse Effects of Vaccines: Evidence and Causality).
Why Placebo-Controlled Trials Are Not Always Used in Vaccine Research
The interview also implied that vaccines are unsafe because many vaccine trials do not use inert placebo controls. This claim overlooks an important ethical principle in medical research.
Placebo-controlled trials are commonly used when no effective treatment or preventive measure already exists. However, once an effective vaccine has been developed to prevent a serious disease, withholding that protection from study participants by giving them an inert placebo may expose them to unnecessary risk.
For this reason, many vaccine trials compare new vaccines to existing licensed vaccines rather than inert placebos. This approach, known as an active comparator trial, allows researchers to evaluate the safety and effectiveness of the new vaccine while still providing participants with protection against the disease.
This practice is consistent with internationally recognized ethical standards for human research. The Declaration of Helsinki, which governs medical research involving human subjects, states that placebo-controlled trials should not be used when doing so would deny participants access to an effective intervention. (World Medical Association, Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects).
Regulatory agencies such as the FDA and the World Health Organization recognize that vaccine trials may appropriately use active comparators when an effective vaccine already exists. This approach ensures that new vaccines can be evaluated safely and ethically while maintaining scientific rigor. (WHO, Guidelines on Clinical Evaluation of Vaccines).
Post-Licensure Safety Monitoring
Safety evaluation does not end when a vaccine is approved.
After licensure, vaccines continue to be monitored through multiple surveillance systems that track safety across millions of doses administered. In the United States, these systems include:
the Vaccine Adverse Event Reporting System (VAERS)
the Vaccine Safety Datalink (VSD)
the Clinical Immunization Safety Assessment (CISA) Network
These systems allow researchers and public health agencies to detect extremely rare adverse events that may not appear during clinical trials and to continuously evaluate vaccine safety in the population. (CDC, Vaccine Safety Monitoring Systems).
Together, the processes of preclinical research, phased clinical trials, regulatory review, and ongoing safety monitoring form the foundation of modern vaccine safety evaluation.
Claim: “Measles Was Not a Serious Public Health Threat”
The interview also suggested that measles deaths were minimal prior to vaccination and therefore the disease was not a significant public health concern.
This framing relies on a selective interpretation of the historical record.
While it is true that measles mortality declined significantly in the United States during the early 20th century due to improvements in sanitation, nutrition, and medical care, measles remained a major public health problem before the introduction of the measles vaccine in 1963.
According to the Centers for Disease Control and Prevention (CDC), before vaccination became widespread in the United States, measles infected approximately 3 to 4 million Americans each year. Of those infections, roughly 48,000 people were hospitalized annually, about 1,000 individuals developed encephalitis (brain inflammation), and 400 to 500 people died each year (CDC, History of Measles in the United States).
These numbers illustrate why focusing solely on mortality can be misleading. Even when death rates declined, measles continued to cause large numbers of hospitalizations and serious complications, particularly among young children.
Measles and Neurological Complications
One of the most serious complications associated with measles infection is measles encephalitis, an inflammatory condition affecting the brain. Encephalitis can result in permanent neurological damage, including cognitive impairment, seizures, hearing loss, and developmental disabilities.
Another rare but devastating complication is subacute sclerosing panencephalitis (SSPE), a progressive neurological disorder caused by persistent measles virus infection in the brain. SSPE typically develops years after the initial measles infection and is almost always fatal (National Institute of Neurological Disorders and Stroke, Subacute Sclerosing Panencephalitis Information Page; World Health Organization, Measles Fact Sheet).
Research has also shown that measles infection can produce what scientists call “immune amnesia.” This occurs when the virus damages immune memory cells, weakening the body’s ability to fight other infections for months or even years after recovery. A 2019 study published in Science found that measles infection can significantly reduce preexisting immune protection against other pathogens (Mina et al., Science, 2019).
Measles Outbreaks Today
Despite the availability of a highly effective vaccine, measles outbreaks still occur when vaccination coverage declines. In the United States, most recent outbreaks have been linked to clusters of unvaccinated individuals, often in communities with low vaccination rates or among international travelers who introduce the virus into susceptible populations (CDC, Measles Cases and Outbreaks).
Globally, measles remains a significant public health concern. The World Health Organization estimates that measles caused approximately 136,000 deaths worldwide in 2022, primarily among unvaccinated children (World Health Organization, Measles Fact Sheet).
These statistics highlight the central point often lost in debates about measles: vaccination dramatically reduced the number of infections, hospitalizations, and severe complications associated with the disease.
The fact that measles deaths declined before the vaccine was introduced does not mean the disease was harmless. Rather, it reflects broader improvements in living conditions and medical care that reduced mortality from many infectious diseases during the same period.
Vaccination ultimately addressed a different problem—preventing the millions of infections and serious complications that continued to occur each year.
Claim: “There Are No Studies Showing Vaccines Do Not Cause Autism”
The interview repeatedly asserted that there are no studies showing that vaccines do not cause autism. This claim misrepresents both the scientific literature and the legal history of autism-related vaccine litigation.
Multiple large epidemiological studies involving hundreds of thousands to millions of children have examined potential links between vaccines and autism spectrum disorders. These studies have consistently found no causal relationship between vaccines and autism. Research conducted in multiple countries—including Denmark, Sweden, the United States, and Japan—has repeatedly examined vaccination status and autism diagnoses across large populations without finding evidence that vaccines increase the risk of autism. (See, e.g., Hviid et al., Annals of Internal Medicine, 2019; Taylor et al., Vaccine, 2014).
Autism Claims Were Extensively Litigated in Vaccine Court
Claims that vaccines cause autism were litigated extensively within the Vaccine Injury Compensation Program, particularly through the Autism Omnibus Proceeding. Beginning in the early 2000s, thousands of petitions were filed in vaccine court alleging that vaccines—most prominently the measles, mumps, and rubella (MMR) vaccine or vaccines containing the preservative thimerosal—caused autism.
To address these claims efficiently, the Court of Federal Claims consolidated several representative cases and conducted lengthy evidentiary hearings involving expert testimony, epidemiological studies, and scientific literature. After reviewing the evidence, the Special Masters issued detailed decisions rejecting the theory that vaccines cause autism.
The court ultimately concluded that the evidence presented did not establish a causal link between vaccines and autism. As a result, the test cases in the Autism Omnibus Proceeding were denied. While individual claims can still be brought under different factual circumstances, the litigation established that, based on the available evidence, a direct causal connection between vaccines and autism had not been demonstrated within the Vaccine Injury Compensation Program.
The Role of the Wakefield Study
One of the most widely cited pieces of evidence used to support the claim that vaccines cause autism was a 1998 study published in The Lancet by British physician Andrew Wakefield. The study suggested a potential connection between the MMR vaccine and autism.
However, subsequent investigations revealed serious problems with the study. In 2011, an investigation published in the British Medical Journal concluded that Wakefield had manipulated patient data and misrepresented clinical findings in the research (Godlee, Smith & Marcovitch, BMJ, 2011).
The investigation found that several of the children described in the study had medical histories that were altered or inaccurately reported in order to support the hypothesis linking the MMR vaccine to autism. Additional conflicts of interest were also uncovered, including undisclosed financial arrangements related to litigation against vaccine manufacturers.
As a result of these findings, The Lancet fully retracted the Wakefield paper, and Wakefield lost his medical license in the United Kingdom. The study is now widely regarded as one of the most prominent examples of scientific misconduct in modern medical research.
What the Scientific Literature Actually Shows
The claim that there are “no studies showing vaccines do not cause autism” is also misleading from a scientific perspective.
In epidemiology, researchers typically examine whether exposure to a factor increases the risk of a particular condition. When large, well-designed studies repeatedly fail to find an increased risk, the scientific conclusion is that no causal relationship has been demonstrated.
Numerous population-based studies have examined whether vaccines increase the risk of autism. These studies include large cohort analyses involving hundreds of thousands—and in some cases over one million—children. The consistent finding across this research is that vaccination does not increase the risk of autism spectrum disorder.
In other words, the available scientific evidence does not support the claim that vaccines cause autism.
A More Nuanced Issue: Vaccine-Associated Encephalitis
While the direct vaccine–autism theory has not been supported by the evidence, there is credible medical literature showing that vaccines can, in extremely rare cases, cause encephalitis, which is inflammation of the brain.
Both the MMR vaccine and certain other vaccines have been associated with rare instances of encephalitis. Encephalitis can cause neurological injury, including cognitive and developmental impairments. In some cases, children who suffer encephalitis may later develop symptoms consistent with autism spectrum disorders.
The Vaccine Injury Compensation Program recognizes this possibility. Claims involving vaccine-related encephalitis are routinely evaluated and, when causation is established, compensated through the program.
This distinction is important. While vaccine court has rejected the theory that vaccines directly cause autism, it does recognize that vaccine-induced neurological injuries such as encephalitis can lead to long-term neurological impairment, which in some cases may present with autism-like symptoms.
The Current Scientific Consensus
The broader scientific consensus remains that vaccines have not been shown to increase the risk of autism. Claims to the contrary generally rely on misinterpretations of the literature or on studies that have been discredited.
That does not mean the science surrounding autism is complete. Autism spectrum disorder is a complex condition that likely involves multiple genetic and environmental factors. Continued research is needed to better understand the causes of autism and how best to support individuals and families affected by it.
But the assertion that there are no studies examining vaccines and autism—or that vaccines have been shown to increase the risk of autism—is not supported by the scientific evidence currently available.
Why the Rogan–Siri Narrative Ultimately Harms the Vaccine Injury Compensation Program
The irony of much of the Rogan–Siri conversation is that while it raises concerns about vaccine injuries and pharmaceutical accountability, the narrative presented ultimately undermines the very system designed to help individuals who believe they were injured by vaccines.
The Vaccine Injury Compensation Program exists precisely because Congress recognized two realities. First, vaccines are one of the most important public health tools ever developed. Second, like any medical intervention administered to millions of people, rare adverse events can occur. The Vaccine Act created a framework intended to balance those two realities by ensuring that individuals who experience rare vaccine-related injuries have access to a fair compensation system.
When discussions about vaccine law become dominated by sensational claims—such as the idea that vaccines are uniquely shielded from accountability or that the compensation system exists to hide vaccine injuries—it erodes public understanding of how the system actually works.
In reality, the Vaccine Injury Compensation Program was designed to make compensation more accessible, not less. Petitioners in vaccine court are not required to prove negligence, product defect, or wrongdoing by vaccine manufacturers. Instead, they must demonstrate that it is more likely than not that the vaccine caused the injury, a significantly lower evidentiary burden than what is required in traditional pharmaceutical litigation.
For many injured individuals, this framework offers a far more realistic path to compensation than attempting to litigate complex pharmaceutical product liability cases in state or federal court.
Unfortunately, narratives that portray the Vaccine Act as a system designed to shield pharmaceutical companies from accountability can discourage injured individuals from pursuing claims through the very program that exists to help them.
A Missing Piece in the Conversation: COVID Vaccines and the VICP
Perhaps the most important issue that received little attention in the Rogan interview is that COVID-19 vaccines are not currently covered by the Vaccine Injury Compensation Program.
Instead, injuries related to COVID vaccines fall under the Public Readiness and Emergency Preparedness Act (PREP Act), which places those claims within the Countermeasures Injury Compensation Program (CICP).
The CICP operates very differently from the VICP. It provides significantly more limited compensation, offers little opportunity for judicial review, and historically has compensated very few claims.
As a result, individuals who believe they were injured by COVID vaccines face a far more difficult path to obtaining compensation than individuals injured by vaccines covered under the VICP.
A Practical Solution Exists
If the goal is truly to help individuals who believe they were injured by vaccines, one of the most meaningful reforms available would be to move COVID vaccines into the Vaccine Injury Compensation Program.
The Secretary of Health and Human Services has the authority to add vaccines to the Vaccine Injury Table and bring them within the VICP framework.
Interestingly, Aaron Siri has served as legal counsel to Health and Human Services Secretary Robert F. Kennedy Jr.
If the focus of the Rogan discussion is genuinely on improving accountability and helping vaccine-injured individuals, advocating for the inclusion of COVID vaccines within the VICP would be a far more constructive step than promoting narratives that undermine public confidence in the existing compensation system.
The Conversation We Should Be Having
Public debates about vaccines often become polarized, with discussions drifting into ideology rather than focusing on practical policy solutions.
But the question that should be at the center of the conversation is simple:
If society encourages vaccination for the public good, how do we ensure that the small number of individuals who experience vaccine injuries are treated fairly?
The Vaccine Injury Compensation Program was created to answer that question.
Strengthening the program—and ensuring that it covers the vaccines people receive—would do far more to support injured individuals than rhetoric that misrepresents how vaccine law actually works.
Why Accuracy Matters
Public conversations about vaccines often become polarized and ideological. But vaccine injury compensation is not a partisan issue, and it should not be reduced to sensational talking points designed to generate clicks or controversy.
Suggesting on a major public platform that vaccines are unsafe because they are not properly tested is a serious claim. It is also critically incorrect. Vaccines undergo extensive clinical testing, regulatory review, and ongoing safety monitoring before and after they are introduced into the public health system. These safeguards exist precisely because vaccines are administered to large populations, including children.
At the same time, acknowledging that vaccines are overwhelmingly safe does not mean ignoring the reality that rare adverse events can occur. That recognition is exactly why Congress created the Vaccine Injury Compensation Program.
The VICP represents a unique legal framework designed to balance two important goals: maintaining a stable and reliable vaccine supply while ensuring that individuals who experience rare vaccine-related injuries have access to a meaningful compensation system.
When discussions about vaccine law become dominated by sensational rhetoric or misleading claims, it undermines public understanding of both vaccine safety and the legal protections that exist for those who are injured. That confusion can discourage people from pursuing legitimate claims through the system designed to help them.
Accuracy and truth matter—particularly when the topic is public health.
Educating the public about the safety and effectiveness of vaccines must go hand in hand with educating them about the legal safeguards in place when rare injuries occur. Setting the record straight ultimately benefits everyone: the public, the legal system, and most importantly, the individuals and families who rely on the Vaccine Injury Compensation Program when rare vaccine injuries occur.